The time between the two injections of the Sputnik V coronavirus vaccine can be extended up to 180 days and will remain effective, as assured this Friday by Russian Direct Investment Fund (RDIF).
// The average number of coronavirus cases in the last week registered the lowest number in three months
An official of the RDIF, who markets the serum outsideof Russia, made the claim in a statement after some countries decided to expand the gap between the first and second doses of the immunization developed in Moscow.
The Argentina was one of the nations that increased the time gap to ensure that as many people as possible receive at least one dose, although days ago the government of the City of Buenos Aires announced that it will advance the application of the second dose in its district. While another state like Kazakhstan has pointed out that a longer interval between both injections gives a stronger immune response.
Last April Alexander Gintsburg, director of the Instituto Gamalea, who developed the vaccine, had noted that the gap between injections could widen up to a maximum of 90 days from 21 initially planned.
The RDIF official cited Gamaleya’s trials showing that the longest gaps had secured a better answer immune, although he did not elaborate on the tests. Yet at the same time denied that the new Russian position on the time between the two doses was related to the delay in delivery of the second component to other countries.
In this sense, the Russian fund has already notified all its foreign partners and vaccine buyers that prolonging the gap between doses to 90 days helps to increase slightly the immune response. This despite the fact that the distribution of the vaccine in Russia involves giving people the second dose of Sputnik V after 21 days.
In turn, the Food and Drug Administration of Philippines said this week that it would allow an interval of 42 days between doses, after Russia proposed extending the time interval to 90 days.
The City, in the opposite direction
Russia’s new recommendation on the time to apply both doses of Sputnik V runs counter to the current position of the Buenos aires city, that in the last days announced that will advance the deadlines so that its inhabitants can receive the second injection of the serum against the coronavirus.
// “This is a horror movie”: the drama of Gerardo, one of the stranded passengers who will return to Argentina
The Buenos Aires Minister of Health, Fernan Quirós, announced last Monday in TN that the district will intensify the application of the second doses of immunizations against Covid-19 in order to prevent the arrival of the Delta variant to Argentina. He also detailed what will be the interval between both serums, according to the immunization that each person has received in the metropolitan area.
“These new variants confirm that the change of strategy that we have decided in recent weeks to refocus and intensify the second doses is what corresponds in this period, “said the official.
As planned, laboratories Richmond received in the last hours the 560 liters of the active principle to produce component 2 of the Sputnik V vaccine against him coronavirus. In this way it is anticipated that by the middle of this month they will be available more than 1 million doses to complete the vaccination schedule for those who already have the first application.
The firm specified that, if everything progresses as planned, the estimated date for the availability of the vaccines is next. July 16th. There will be 1,362,125 Component 1 doses Y 1,005,000 doses of component 2.
Days ago, Richmond had confirmed that it had finished the first 153,441 doses of Sputnik V Component 2, of which they sent a sample to Moscow to carry out the corresponding control.
In addition, the laboratory based in Argentina It has produced two batches of component 1, one of 448,625 doses that ended on June 18 and another of 550 thousand doses that ended last Friday. Samples of both batches (80 vials for each batch) are also in the Gamaleya awaiting confirmation to be able to begin their distribution.
Weeks ago, Marcelo Figueiras, president of the laboratory, indicated to Télam that “the Gamaleya promised to finish his verifications as soon as possible final but have a lot of analysis to do. We have the tranquility of having checked it ourselves and that they gave everything well, “he said.
It is estimated that the first batch, which has been with the logistics operator for more than 15 days, may be “released” for application next week, after the confirmation of the Gamaleya. Meanwhile, for the following batches it is expected that the process of sending tests, control by the Russian research center and release to be applied does not exceed 20 days.
Currently, the Richmond plant in Pilar performs the formulation, filtering and filling of vials (packaging), a complex technical and scientific process with demanding requirements of good manufacturing practices.
To carry out this process, the laboratory receives the active ingredient of the vaccine made in Gamaleya. “This process is not a simple ‘bottling’, it requires highly complex and important technical and scientific knowledge”, highlighted Figueiras.
“It involves the work of many professionals both for production and for control; that is, it is not simply a mechanical or technological process, it is a scientific work“added the businessman.
The next stage will consist of the complete production of the vaccine in the new plant that the laboratory is also building in Pilar. “The new plant is designed to produce up to 500 million doses per year and there it could be done from the active principle to the packaging, that is, the complete production “, according to Figueiras.
Another flight of Argentinian airlines arrived in the country at dawn this Friday from Moscow with a departure of more than 1.1 million Sputnik V vaccines. With this new shipment, which represents a record amount of doses transported in a single plane, Argentina managed to exceed the 26 million vaccines received since the beginning of the operations to supply the national immunization plan against the coronavirus.
The Airbus 330-200, registration LV-GIF, landed at Ezeiza international airport around 4.47 in the morning with 1,141,000 doses of component 1 of the vaccine manufactured by the Gamaleya Institute.
The transfer of this record quantity of drugs was made possible by a change in the boxes that allowed a consolidation of a higher volume of doses, which made it possible to transport a greater number of units.
Until now, the maximum number of doses that the flag line could carry in a single trip was last June 3, when 815,150 doses of Sputnik V. landed in Ezeiza at night.
With this new arrival the 28th Flag Line Operation for Vaccines, which in this case was carried out by the same plane that arrived last Tuesday from Russia with more than 709 thousand doses of Sputnik V vaccines. Thus, this week Argentina received a total of 1,850,085 doses from Russia.
The 709,085 Sputnik V vaccine dose (359,085 doses of component 1 and 350,000 doses of component 2), which arrived in the country on Tuesday on flight AR1061, along with a remnant of 8,115 units (2,715 from 1 and 5,400 from 2), began to be delivered today in the 24 jurisdictions, with the objective of continuing to deepen the implementation of the Strategic Vaccination Plan.
On the other hand, a new record was reached in June with a total of 8,410,643 applications nationwide, with a daily average of 280,355 immunizations, while the arrival of vaccines also marked a historical figure with 8,074,785 doses.
With the new shipment, a total of 26,847,730 doses have already arrived in the country, of which 11,265,830 corresponded to Sputnik V, (9,375,670 of component 1 and 1,890,160 of component 2); 6 million at Sinopharm; 580,000 to AstraZeneca-Covishield, 1.944.000 a AstraZeneca by the WHO COVAX mechanism, and 7,057,900 to AstraZeneca and Oxford whose active principle was produced in Argentina.
According to data from the Public Vaccination Monitor, Until this Thursday, 24,944,091 vaccines were distributed in all jurisdictions, of which 20,907,721 have already been applied: 16,821,968 people received the first dose and 4,085,753 have the full two-dose schedule.
The news came as a surprise at a time when in Argentina the application of the reinforcement of vaccines against the coronavirus is delayed: the British Ministry of Health said that a single dose of Pfizer Y AstraZeneca it is only 33% effective against the Indian variant.
You must have the complete scheme to “obtain the maximum protection”Against a strain considered more lethal and contagious and that brought the Indian health system to its knees.
// He had received two doses of the Sputnik vaccine and a nurse at Santojanni Hospital died of coronavirus
According to the official British report known this Monday, “the effectiveness of the vaccine against the symptomatic disease of variant B.1.617.2 (India) is similar after two doses compared to the dominant variant B.1.1.7 (British) in the United Kingdom. “We expect to see even higher levels of effectiveness against hospitalization and death,” he predicted.
The results released by London were encouraging based on the cases detected in those people who received both doses of one of these two vaccines.
In that sense, the vaccine Pfizer-BioNTech was 88% effective against symptomatic disease of the Indian variant two weeks after the second dose, compared with 93% effectiveness against the British variant.
While, two doses of AstraZeneca vaccine were 60% effective against symptomatic disease of the Indian variant compared to 66% effectiveness against the British variant. Both vaccines reportedly were 33% effective against symptomatic disease B.1.617.2 (india), three weeks after the first dose compared to about 50% effective against variant B.1.1.7 ( British) ”.
// The COVID-19 genome would show that it was made in a laboratory
According to the report, the difference in effectiveness between the vaccines after two doses can be explained by the fact that the application of the second AstraZeneca doses was later than for the Pfizer-BioNTech vaccine in the UK. Other data on antibody profiles show that it takes more time to reach maximum effectiveness with AstraZeneca.
What the British Health Minister said
The British Health Minister, Matt Hancock, said that “this new evidence is groundbreaking and demonstrates how valuable the COVID-19 vaccination program is in protecting the people we love.”
Matt Hancock, British Health Minister
It is clear how important the second dose is to ensure the strongest possible protection
“Now we can be sure that more than 20 million people, more than 1 in 3, have significant protection against this new variant, and that number is increasing by hundreds of thousands every day as more and more people receive it. second vital dose. I want to thank the scientists and doctors who have been working around the clock to produce this research. It is clear how important the second dose is to ensure the strongest possible protection against COVID-19 and its variants, and I urge everyone to reserve its application when it is offered, “he said.
In turn, Mary Ramsay, head of immunization for the British public health system, stated that “this study provides reassurance that two doses of any of the vaccines offer high levels of protection against symptomatic disease of variant B.1.617. 2 (india). We hope that vaccines will be even more effective in preventing hospitalization and death, so it is vital to obtain both doses to obtain maximum protection against all existing and emerging variants “,Indian.
What about the other vaccines
Few studies are currently known in the world on the efficacy of different vaccines against the most contagious strains of COVID-19. In the case of the Indian variant, the Nikolai Gamaleya Center for Epidemiology and Microbiology in Moscow announced in mid-May that it would soon study the effectiveness of Sputnik V against this strain.
“We will begin to test the effectiveness of Sputnik V against this variant,” the director of the institution Alexandr Gintsburg told the Russian news agency Sputnik at the time. Since then no results on these investigations have been revealed.
The Russian scientist was optimistic about the results of the study. “The Russian vaccine, of course, will be able to with that mutation, since, thanks to the booster vaccination, Sputnik V creates a very high reserve of antibodies virus neutralizers ”, he assured.
// New restrictions: what are the measures that the government is analyzing and in what month it plans to relax the closures
In Argentina, two imported cases of the Indian variant have been officially detected in two minors who arrived from Europe in mid-May. There is no community circulation of this strain in the country.
But the Russian vaccine proved effective against the variant of Manaos with the application of its two components, according to a study carried out by the Institute of Virology of the National University of Córdoba.
“A study carried out in Argentina has confirmed the high efficacy of the Sputnik V vaccine against new strains of coronavirus. Argentina was the first Latin American country to use Sputnik V for the vaccination of its inhabitants, and now we see that the use of this drug helps to protect the population not only against known ones, but also against new variants of the virus, including the Brazilian. In addition, a strong immune response develops after receiving the first dose of the vaccine, “he said. Kirill Dmitriev, director of the Russian Fund for Direct Investment.
For the strains that circulate in Argentina, the Sputnik V vaccine reduces the probability of symptomatic disease by 91%, and mortality and severe forms that require hospitalization by nearly 100%, according to the Gamaleya Institute.
In the case of Covishield – manufactured by an Indian laboratory with the formula of the pharmaceutical company AstraZeneca and the University of Oxford – it reduces symptomatic disease by between 70 and 80% and its serious forms by close to 100%.
// Why are there people who with the complete vaccination scheme die from coronavirus
Sinopharm, produced by the Chinese state laboratory of the same name, has an efficacy of 79.34% according to the first interim analysis of the results of the Phase 3 trial, and participants who received two doses produced a high level of antibodies against it. SARS CoV-2 at a rate of 99.52%, according to Telam.
However, there are no known studies that specify the efficacy of this vaccine against the Indian variant of the virus.
Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), stated that the approval of the Russian vaccine Sputnik V against him COVID-19 wait a technical definition of the specialists. In turn, he affirmed that so far it cannot be anticipated when it will be adopted.
In the middle of the videoconference at the International Economic Forum of St. Petersburg the WHO director was asked whether the approval of the Russian vaccine by the WHO will take weeks or months. Ghebreyesus said that these specialists are part of “a group that works independently and that will report on its conclusions once it completes its work.”
Given the lack of approval, the WHO so far included only Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, Moderna y Sinopharm, within the list of use in emergencies for all countries.
Why does this affect Argentina? Because Spain, one of the countries that so far excluded Sputnik V from its vaccination plan, reported that only those Argentines who have a complete vaccination schedule with Sinopharm.
“Since June 7, all vaccinated people and their families are also welcome to our country, Spain, regardless of their place of origin ”, was the statement issued by the Spanish government.
// Due to a rare case of thrombosis, Chile suspended vaccination with AstraZeneca in children under 45 years of age
At the same time Ghebreyesus stressed that the appearance of the anticovid vaccines “showed the light at the end of the tunnel”, But at the same time he stressed that there is a need for them to reach all the countries of the world.
In addition, from the WHO, they proposed as an objective that for september this year is vaccinated at least on 10% of the population of each country and 30% by the end of 2021.
The WHO director made it clear that “no one is safe while we are not all “, and insisted that efforts are needed “Jointly” to fight the pandemic.
The Russian President, Vladimir Putin, stated, at the end of last March, that September of this year would be a key month, since there could be 70%of its vaccinated population. Despite these expectations, the vaccination campaign in Russia it is moving slowly due to the reluctance of its inhabitants.
For his part, the Russian Minister of Health, Mijaíl Murashko, said that, although the vaccination is of the 30 or 40% of the population, it does not provide herd immunity. He also indicated that some specialists argue that this immunity can be achieved only with the vaccination of the 80-90 %, although that is not the official position of his portfolio.
// The United States will donate vaccines against the coronavirus to Argentina: it will allocate six million doses to Latin America
According to Murashko, to this day almost 15 million Russians they were vaccinated with the full schedule.
The Director of the WHO Emergency Program, Michael Ryan, in another panel of the Forum dedicated to the pandemic, warned that, although there is a decrease in covid-19 cases, the situation “it’s still complex and the risks remain very tall”.
“The pandemic continues to be a serious catastrophe. All countries need to take important action. No one can relax and we must be prepared for a future pandemic. If we do not prepare we will have to pay a high price”, He expressed Ryan
He also highlighted the risks of unequal distribution of vaccines among States, as well as the Social inequality in the provision of health services within the same country, which, in his opinion, may be due to poor management.
Labs play the race to have the perfect antidotes against coronavirus for minors. The United States, producer of several of the drugs that generate immunity against SARS-CoV-2, has already authorized the use of the Pfizer-BioNTech in minors between 12 and 15 years. While, Modern proved to be effective in adolescents between 12 and 17 years and had no new or major safety issues in a clinical trial, which could set the stage for a second inoculation to school-age children that would be authorized in July.
The essay of Modern (licensed for adults over 18 years of age) evaluated the formula in 3,732 adolescents ages 12 to 17, two-thirds of whom received the vaccine and one-third a placebo. The main objective was to produce a immune response on par with that seen in the company’s large phase 3 trial in adults, which had a 94.1% effectiveness in the prevention of COVID-19. It took US regulators about a month to review a similar study from Pfizer / BioNtech, which was licensed for ages 12-15 last. May 10. If Moderna receives the same treatment, her authorization would arrive in early July.
// What measures work and what not to prevent coronavirus infections
What about the vaccines that are applied in Argentina
The prospects with the AstraZeneca, the Sputnik V and the Sinopharm for minors are not very encouraging so far. To this, it is added that the vaccination plan in the country advances at a slow pace in adults.
The developers of the Russian vaccine Sputnik V they showed their anger in front of the delay from approval for the application of its antidote in minors. Alexander Ginzburg, director of the Gamaleya Center, said in dialogue with the Russian agency Ría Novosti: “We are starting to lag behind and will do so irrevocably soon. I mean, our children will not be protected, despite the fact that we were the first to register the vaccine (for minors) ”.
// Some coronavirus vaccines could be the key to creating a universal cancer formula
Ginzburg insisted in the Russian media about the need to“get permission to use Sputnik V vaccineIn children”. In addition, he stated that “adolescents over 14 have no physiological contraindications” with his vaccine. However, delays in its approval will inevitably impact Argentina.
Regarding the Chinese vaccine Sinopharm -also administered in the country-, there is no news about the immunization of minors. Something similar happens with the vaccine Oxford-AstraZeneca, since, in England, it was suspended their trial (it was in phase 2) which was carried out on 300 volunteers between the ages of 6 and 17.
// What is the “black fungus” that has already registered a case in Uruguay: it is related to COVID-19 and diabetes
After the global controversy generated by the thrombosis cases In some adults who had been inoculated with AstraZeneca – now banned in several countries – research on the effectiveness of the antidote in boys and adolescents came to nothing.
What he knows so far is that the suspension of trials will last until the UK Medicines Regulatory Agency (MHRA) provides further information on possible Adverse effects of this vaccine. “Although there is no concern about the safety in the pediatric clinical trial, Oxford decided to wait for additional information from the MHRA in its investigation of rare cases thrombosis before administering more vaccines, ”they said. With Sputnik stuck and little news from the other pharmaceutical companies, it seems that vaccines for minors they are far from being applied shortly in Argentina.
The Russian Direct Investment Fund (RDIF) announced this Thursday an agreement with the United Nations Children’s Fund (UNICEF) for the supply of 220 million doses of Russian coronavirus vaccine Sputnik V. The delivery, confirmed the Russian body, will take place once the World Health Organization (WHO) authorizes the emergency use of the drug, a process that began in October last year.
“RDIF and Unicef announce the signing of the agreement for the supply of 220 million doses of the two-component vaccine Sputnik V. That amount is enough to immunize 110 million people“the Russian entity reported in a statement.
“RDIF is pleased to support the international efforts of UNICEF and its partners to ensure equitable and widespread access to vaccines against the coronavirus for all countries, “said the executive director of the RDIF, Kirill Dmitriev after the dissemination of the agreement.
“Sputnik V is already used in more than 40 countries, and this number continues to increase as we continue to deliver to our partners every day, “added the manager, while insisting that vaccination is the best way to beat the pandemic, help people feel safe, restore economies and return to normal life.
The supply to Unicef, clarified the RDIF, is subject to Sputnik V emergency clearance by the World Health Organization (WHO). In that sense, the Russian body hopes that the decision will be announced “soon”, given that it requested the approval of the WHO in October 2020.
Dmitriev also announced that talks will be held with the Global Alliance for Vaccines and Immunization (GAVI) to discuss the possibility of including Sputnik V in the Covax mechanism, created by WHO to ensure equitable access to coronavirus vaccines for all countries, regardless of income.
Sputnik V was approved in Russia on August 11, 2020 and consists of two doses applied with an interval of 21 days. While the former is based on human adenovirus type 26, the latter uses recombinant human adenovirus type 5.
Although we would love to make a note about the adventures of the lady as a heroine or a vigilante, the truth is that vaccines do not generate magnetic attraction … Conspiracy theories and misinformation.
Antiquarantine complains about the magnetized mother. (Photo and video: Twitter / LautaroMaislin; photo: Twitter / Oscarrrevistas68).
In a new demonstration against quarantine, in Rosario, a man threatened a local journalist and threw a unusual complaint against the vaccine Sputnik Vthat made it viral: accused her of generating magnetism. The march had been organized by a group called “Doctors for the Truth.” It seems a joke, but it is not.
“They put it on my old woman, who has no information about what she has. I put a magnet on him and it stuck to his arm… the vaccine has a magnet, nobody notices that!”The protester shouted.
// The surprising appearance of Oriana Sabatini in the video of a famous tiktoker
The truth is that although it seems new, the issue of “magnetized vaccines” or with 5G, for Bill Gates to control us (!), is not new: It is a conspiracy theory that continues to spread and that, unfortunately, is not true. We would love to have antibodies against Covid-19 and wireless connectivity so we don’t depend on the data connection or magnetism!
While we were thinking about the name of a superheroine for this woman (our first options are “magnet-Woman” or “the magnetism girl”), in the networks many shared memes about the unusual antiquarantine lord theory (or according to some tweeters, with whom we may or may not agree, one of many “covidiots” who seem not to understand that we are experiencing a pandemic).
Our favorite meme? The one of “the young hands of vaccines”.
And if we talk about superpowers and magnetism, he could not be missing, the villain of the X-Men, Magneto.
True true!! What that man says with the Argentine flag The same thing happened to my uncle! They gave him the spuknic !! 😂😂😂 pic.twitter.com/Tkfjuu1Qjq
Several videos in which it is ensured that after receiving a Covid-19 vaccine the injection site is magnetized were shared thousands of times on social networks. According to the posts, this is because vaccines contain microchips, heavy metals, or even a “tracking device”.
But all claims are false. The objective of vaccines is to generate an immune response against the coronavirus and these do not contain any components capable of producing a magnetic attraction.
“I am with a patient who has been vaccinated with the AstraZeneca vaccine. I just had a magnet here in the office and I am testing that the magnet does stick in the place where she received the vaccine ”, is heard in one of the sequences that circulate on social networks and WhatsApp groups.
viral medical magnetism
“Not. Receiving a Covid-19 vaccine cannot cause your arm to become magnetized. This is a plain and simple deception, ”said Dr. Stephen Schrantz, an infectious disease specialist at Chicago Medical University.
“There is absolutely no way that a vaccine can cause the reaction shown in these videos.”, He added.
Theories about suspicious or secret “components” in immunizations against Covid-19 began to circulate months before the emergency approval of the first vaccines, in December 2020. However, their compositions are not secret. Those of Pfizer, Moderna, AstraZeneca, Sputnik or Sinopharm, to give a few examples, have been published by health authorities.
// The owner of a phone shop is convicted of using a pirated version of Windows on two computers
Thomas Hope, a vaccine researcher and professor of cell and developmental biology at Northwestern University Feinberg School of Medicine, told the news agency AFP: “There is nothing in vaccines that a magnet can interact with; there are proteins, lipids, salts, water, and chemicals that maintain the pH. That’s basically it, so (what is shown in the videos) is not possible ”.
Dr. Nicolás Torres, from the IBYME-CONICET Immunopathology Laboratory, Argentina, agrees with him: “What the video shows is not even scientific,” he told AFP Factual, specialized in data checking. “In vaccines there is genetic material, proteins, some sugar. Y none of these molecules have strong magnetic properties to stick a magnet”, He added.
Hope pointed out that even if the vaccines had traces of a metallic substance, “they would have to place a fairly substantial piece of metal under the skin so that the magnets stick, ”adding that this is impossible to administer through a needle.
Introduced last month, the iMac M1 will arrive at its first customers on May 21. In the meantime, Apple has already sent some demo copies to the press and journalists have rushed to run tests on GeekBench. We can therefore consult the first figures, with an average score of 1,724 in single-core and 7,453 in multi-core. This is unsurprisingly very close to the scores of other Macs equipped with the Apple M1 chip.
By comparison, the entry-level 21.5 “iMac, with a 2.3 GHz dual-core Core i5, achieved scores of 841 in single-core and 1,981 in multi-core. The first 4K model, with a quad-core Core i3 clocked at 3.6 GHz, climbs to 897 in single-core and 3,182 in multicore. And the most powerful Intel model, with a hexacore Core i7 running at 3.2 GHz, climbs to 1,109 in single-core and 6 015 in multicore Whatever the point of comparison, we are therefore witnessing a clear surge in power.
This iMac M1 can also be compared to the 27 “models. It easily beats the entry-level model, equipped with a hexacore Core i5 clocked at 3.1 GHz which scores 1,121 in single-core and of 5,876 in multi-core. On the other hand, it is a bit tight to tackle the most muscular models: the Core i9 decacoeur running at 3.6 GHz recorded scores of 1,247 in single-core and 9,004 in multi-core. the second generation Apple Silicon chip which will equip the successors of the current iMac 27 “will make everyone agree.
Links do not appear? Images are missing? Your ad blocker is playing tricks on you. To view all of our content, please turn off your ad blocker!